SLC1A3 and thyroid cancer: (38) thyroid cancer cells with CD133+ had a greater glutamate level than thyroid cancer cells with CD133- and they further suggested that this phenomenon was mediated by the activation of NF-κB signaling to promote the transcriptional levels of glutamate aspartate transporter (SLC1A3), which in turn conferred TCSCs a stronger self-renewal ability.